



#17

PATENT RECEIVED  
MAR 10 2003  
TECH CENTER 1600/2900

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  
Alan Collis, et al.

Examiner: To be determined

Art Unit: 1614

Application No.: 09/871,564

Filed: May 31, 2001

Title: Heteroaryl-cyclic Acetals

I hereby certify that this correspondence, along with any referred to herein as enclosed or submitted herewith, is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on

Date of Deposit March 3, 2003  
Cheryl A. MolleINFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicants submit herewith a list on the enclosed form 1449, and copies of patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement, pursuant to 37 C.F.R. 1.97(h), is not intended to constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention.


Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

Listed reference EP 0146862, a copy of which is enclosed, is in the German language, and no translation is currently available. However, listed reference U.S. Patent No. 4,659,503

is in the same patent family, and is believed to generally cover similar subject matter. These references disclose series of pyridylthiophenes having liquid crystal properties.

This Information Disclosure Statement is being filed within the period set forth in §1.97(b) because it is believed to be filed before the mailing date of a first Office Action on the merits. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) to Deposit Account No. 18-1982, upon which the undersigned is authorized to draw.

Respectfully submitted,



Paul R. Darkes, Registration No. 33,862  
Attorney for Applicants

March 3, 2003  
Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-3638  
Telefax (908) 231-2626  
Aventis Docket No. CA 2295 US CNT

code (WIPO Standard S1.0).<sup>7</sup> <sup>8</sup> Kind of document by the appropriate symbol.<sup>9</sup>  
number of the patent document. <sup>5</sup> Kind of document by English language Translation is attached.  
possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on  
the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.  
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.